197 related articles for article (PubMed ID: 16820176)
1. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation.
Singleton PA; Lingen MW; Fekete MJ; Garcia JG; Moss J
Microvasc Res; 2006; 72(1-2):3-11. PubMed ID: 16820176
[TBL] [Abstract][Full Text] [Related]
2. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation.
Singleton PA; Moreno-Vinasco L; Sammani S; Wanderling SL; Moss J; Garcia JG
Am J Respir Cell Mol Biol; 2007 Aug; 37(2):222-31. PubMed ID: 17395891
[TBL] [Abstract][Full Text] [Related]
3. Opioid partial agonist effects of 3-O-methylnaltrexone in rhesus monkeys.
Platt DM; Rowlett JK; Izenwasser S; Spealman RD
J Pharmacol Exp Ther; 2004 Mar; 308(3):1030-9. PubMed ID: 14634035
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of methylnaltrexone with 5-fluorouracil and bevacizumab on inhibition of vascular endothelial growth factor-induced angiogenesis.
Singleton PA; Garcia JG; Moss J
Mol Cancer Ther; 2008 Jun; 7(6):1669-79. PubMed ID: 18566238
[TBL] [Abstract][Full Text] [Related]
5. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor.
Gorur A; Patiño M; Shi T; Corrales G; Takahashi H; Rangel R; Gleber-Netto FO; Pickering C; Myers JN; Cata JP
J Cell Physiol; 2021 Nov; 236(11):7698-7710. PubMed ID: 34038587
[TBL] [Abstract][Full Text] [Related]
6. Methylnaltrexone potentiates the anti-angiogenic effects of mTOR inhibitors.
Singleton PA; Mambetsariev N; Lennon FE; Mathew B; Siegler JH; Moreno-Vinasco L; Salgia R; Moss J; Garcia JG
J Angiogenes Res; 2010 Feb; 2(1):5. PubMed ID: 20298531
[TBL] [Abstract][Full Text] [Related]
7. Involvement of central mu- but not delta- or kappa-opioid receptors in immunomodulation.
Nelson CJ; Schneider GM; Lysle DT
Brain Behav Immun; 2000 Sep; 14(3):170-84. PubMed ID: 10970678
[TBL] [Abstract][Full Text] [Related]
8. Methylnaltrexone crosses the blood-brain barrier and attenuates centrally-mediated behavioral effects of morphine and oxycodone in mice.
Walentiny DM; Komla E; Moisa LT; Mustafa MA; Poklis JL; Akbarali HI; Beardsley PM
Neuropharmacology; 2021 Mar; 185():108437. PubMed ID: 33316279
[TBL] [Abstract][Full Text] [Related]
9. Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes.
Ho WZ; Guo CJ; Yuan CS; Douglas SD; Moss J
J Pharmacol Exp Ther; 2003 Dec; 307(3):1158-62. PubMed ID: 14560041
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of the opioid antagonist N-methylnaltrexone and evaluation of its effects on gastrointestinal tract function in horses treated or not treated with morphine.
Boscan P; Van Hoogmoed LM; Pypendop BH; Farver TB; Snyder JR
Am J Vet Res; 2006 Jun; 67(6):998-1004. PubMed ID: 16740093
[TBL] [Abstract][Full Text] [Related]
11. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
12. Morphine-6 beta-glucuronide has a higher efficacy than morphine as a mu-opioid receptor agonist in the rat locus coeruleus.
Osborne PB; Chieng B; Christie MJ
Br J Pharmacol; 2000 Dec; 131(7):1422-8. PubMed ID: 11090116
[TBL] [Abstract][Full Text] [Related]
13. Antagonism of peripheral opioid receptors by methylnaltrexone does not prevent morphine tolerance in rats.
Blomqvist KJ; Dudek KA; Viisanen H; Mätlik K; Ahlström FHG; Laitila J; Kalso EA; Rauhala PV; Lilius TO
J Neurosci Res; 2022 Jan; 100(1):329-338. PubMed ID: 32459013
[TBL] [Abstract][Full Text] [Related]
14. Dose-related antagonism of the emetic effect of morphine by methylnaltrexone in dogs.
Foss JF; Bass AS; Goldberg LI
J Clin Pharmacol; 1993 Aug; 33(8):747-51. PubMed ID: 8408737
[TBL] [Abstract][Full Text] [Related]
15. Effects of methylnaltrexone on guinea pig gastrointestinal motility.
Anselmi L; Huynh J; Vegezzi G; Sternini C
Naunyn Schmiedebergs Arch Pharmacol; 2013 Apr; 386(4):279-86. PubMed ID: 23361094
[TBL] [Abstract][Full Text] [Related]
16. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
17. The effects of morphine and methylnaltrexone on gastrointestinal pain in healthy male participants.
Brokjaer A; Olesen AE; Christrup LL; Dahan A; Drewes AM
Neurogastroenterol Motil; 2015 May; 27(5):693-704. PubMed ID: 25810023
[TBL] [Abstract][Full Text] [Related]
18. Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells.
Johnson EA; Oldfield S; Braksator E; Gonzalez-Cuello A; Couch D; Hall KJ; Mundell SJ; Bailey CP; Kelly E; Henderson G
Mol Pharmacol; 2006 Aug; 70(2):676-85. PubMed ID: 16682505
[TBL] [Abstract][Full Text] [Related]
19. A Tyr-W-MIF-1 analog containing D-Pro2 acts as a selective mu2-opioid receptor antagonist in the mouse.
Watanabe H; Nakayama D; Ito K; Watanabe C; Mizoguchi H; Fujimura T; Murayama K; Kawamura S; Sato T; Sakurada C; Sakurada T; Sakurada S
J Pharmacol Exp Ther; 2005 Mar; 312(3):1075-81. PubMed ID: 15561796
[TBL] [Abstract][Full Text] [Related]
20. Orphanin FQ/nociceptin potentiates [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin-Induced mu-opioid receptor phosphorylation.
Ozsoy HZ; Thakker DR; Standifer KM
Mol Pharmacol; 2005 Aug; 68(2):447-56. PubMed ID: 15890842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
